Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

GreenLight Biosciences (GRNA) News Today

GreenLight Biosciences logo
Greenlight Coupon Codes
Greenlight Family Cash Card 2023 Review
RNA company to lay off 96 employees in Lexington
Greenlight Screenwriting Lab
GRNA GreenLight Biosciences Holdings
GreenLight Biosciences Holdings stock logo
Canaccord Genuity Group Begins Coverage on GreenLight Biosciences (NASDAQ:GRNA)
Canaccord Genuity Group began coverage on shares of GreenLight Biosciences in a research note on Thursday. They set a "buy" rating and a $4.00 target price on the stock.
GreenLight Biosciences Holdings stock logo
GreenLight Biosciences (NASDAQ:GRNA) Earns Outperform Rating from Analysts at Credit Suisse Group
Credit Suisse Group started coverage on shares of GreenLight Biosciences in a research report on Friday. They set an "outperform" rating and a $5.50 price target on the stock.
GreenLight Biosciences lays off a quarter of its team
GreenLight Biosciences Holdings stock logo
GreenLight Biosciences Holdings (NASDAQ:GRNA) Sees Significant Decline in Short Interest
GreenLight Biosciences Holdings (NASDAQ:GRNA - Get Rating) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 1,770,000 shares, a decrease of 14.1% from the August 31st total of 2,060,000 shares. Based on an average trading volume of 657,700 shares, the short-interest ratio is currently 2.7 days. Currently, 3.5% of the company's shares are short sold.
GreenLight Biosciences Holdings stock logo
Morningside Venture Investment Acquires 3,061,224 Shares of GreenLight Biosciences Holdings (NASDAQ:GRNA) Stock
GreenLight Biosciences Holdings (NASDAQ:GRNA - Get Rating) major shareholder Morningside Venture Investment purchased 3,061,224 shares of the company's stock in a transaction on Thursday, August 11th. The shares were purchased at an average price of $3.92 per share, for a total transaction of $11,999,998.08. Following the purchase, the insider now owns 15,919,155 shares in the company, valued at approximately $62,403,087.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
GreenLight Biosciences announces $109 million financing
Get GreenLight Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRNA and its competitors with MarketBeat's FREE daily newsletter.

Central Bank Abandons USD (Ad)

You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD!

Get Your FREE Gold Investor Kit NOW!

GRNA Media Mentions By Week

GRNA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GRNA
News Sentiment

0.00

0.48

Average
Medical
News Sentiment

GRNA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GRNA Articles
This Week

0

0

GRNA Articles
Average Week

Get GreenLight Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRNA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:GRNA) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners